Physician profile
Joseph Creely
NPI 1912903469
$3,350.32
in general payments reported to CMS, 2019-2025
24 companies · $455 in 2025
The $455 reported for 2025 was more than what a typical Otolaryngology provider received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $220 · 2020: $243 · 2021: $727 · 2022: $596 · 2023: $652 · 2024: $457 · 2025: $455.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,474 · Education: $90.01.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,474.21 |
| Education | $90.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $1,050.58 | 2021-2025 | Dupixent |
| Genzyme Corporation | $424.38 | 2021-2025 | |
| Stryker Corporation | $417.47 | 2019-2025 | Audion Et Dilation System, Clarifix |
| Kaleo, INC. | $313.01 | 2019-2023 | Auvi-Q |
| Optinose US, INC. | $287.06 | 2020-2023 | |
| Glaxosmithkline, LLC. | $208.99 | 2021-2025 | Nucala |
| Alk-Abello, INC | $88.72 | 2020-2021 | |
| Medtronic, INC. | $85.49 | 2021-2025 | Nuvent |
| Amgen INC. | $63.21 | 2025 | Tezspire |
| Aerin Medical INC. | $60.28 | 2023-2025 | |
| Phadia US INC. | $43.92 | 2021-2022 | |
| Integra Lifesciences Corporation | $43.06 | 2024 | Microfrance, Integra Duo, Codman Isocool Aht |
| Kerecis Limited | $40.92 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide |
| Smith+Nephew, INC. | $32.24 | 2023 | Tula |
| Ars Pharmaceuticals Operations, INC. | $26.37 | 2025 | Neffy |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intersect Ent, INC. | $24.70 | 2021 | |
| Cochlear Americas | $22.40 | 2019 | |
| Uswm, LLC | $20.68 | 2021 | |
| Hikma Pharmaceuticals USA | $18.54 | 2023 | Ryaltris |
| Acclarent, INC | $18.26 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $16.18 | 2025 | Tezspire |
| Checkpoint Surgical, INC | $15.23 | 2021 | |
| Phathom Pharmaceuticals, INC. | $14.85 | 2024 | Voquezna |
| Baxter Healthcare | $13.78 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Creely listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.